

**Hepatitis B  
Stakeholder Comments**

Please enter the name of your registered stakeholder organisation below.

NICE is unable to accept comments from non-registered organisation or individuals. If you wish your comments to be considered please register via the [NICE website](#) or contact the [registered stakeholder organisation](#) that most closely represents your interests and pass your comments to them.

<b>Stakeholder Organisation:</b>		British HIV Association (BHIVA)		
<b>Name of commentator:</b>		Professor Jane Anderson Chair, British HIV Association (BHIVA)		
<b>Order number</b> <i>(For internal use only)</i>	<b>Document</b> Indicate if you are referring to the Full version NICE version or the Appendices	<b>Page Number</b> <b>Number only (do not write the word 'page/pg').</b> Alternatively write ' <b>general</b> ' if your comment relates to the whole document.	<b>Line Number</b> <b>Number only (do not write the word 'line').</b> See example in cell below	<b>Comments</b>  Please insert each new comment in a new row.  Please do not paste other tables into this table, as your comments could get lost – type directly into this table.
<b>Example</b>	<b>Full</b>	<b>16</b>	<b>45</b>	<b>Our comments are as follows .....</b>
<b>Proformas that are not correctly submitted as detailed in the line above may be returned to you</b>				
1	FULL	Page 1	Line 1	BHIVA comment: An emphasis on HIV testing both at diagnosis and pre-initiation of treatment, if different
2	FULL	Page 43 and Page 45	Line 7 Line 24	5 Guideline summary 1 Assessment and referral BHIVA comment: Should include hepatitis A testing with a view to vaccination if non-immune, given the high rate of severe hepatitis in patient who get acute hepatitis A on top of chronic liver disease from other causes (such as HBV)
3	FULL	Page 50 and Page 447	Line 26 First line (not numbered) – paragraph heading “Other considerations”	Recommendation 62 BHIVA comment: BHIVA agrees with the guideline
4	FULL	Page 51 and Page 447	Line 2 Last paragraph (line not numbered)	Recommendation 64 BHIVA comment: BHIVA agrees with the guideline

Please add extra rows as needed

Please email this form to: [hepatitisb@nice.org.uk](mailto:hepatitisb@nice.org.uk)

**Closing date: 5pm on 28 February 2013**

**PLEASE NOTE:** The Institute reserves the right to summarise and edit comments received during consultations, or not to publish them at all, where in the reasonable opinion of the Institute, the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.